Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV
  • Life
  • Health
  • Environment
  • Travel
  • Food
  • Fashion
  • Science
  • Religion
  • History
  • Feature
  • Expat Corner

Russian COVID-19 vaccine passes limited trial test, report says

by French Press Agency - AFP

LONDON Sep 04, 2020 - 2:09 pm GMT+3
The vaccine against the coronavirus disease developed by the Gamaleya Research Institute of Epidemiology and Microbiology, Aug. 6, 2020. (Russian Direct Investment Fund via AFP)
The vaccine against the coronavirus disease developed by the Gamaleya Research Institute of Epidemiology and Microbiology, Aug. 6, 2020. (Russian Direct Investment Fund via AFP)
by French Press Agency - AFP Sep 04, 2020 2:09 pm
RECOMMENDED
Long-term use of antidepressants has been associated with an increase in heart disease. (dpa Photo)

Long-term use of antidepressants linked to increased heart disease

HEALTH

Patients involved in early tests of a Russian coronavirus vaccine developed antibodies with "no serious adverse events," according to research published in The Lancet Friday, but experts said the trials were too small to prove safety and effectiveness.

Russia announced last month that its vaccine, named "Sputnik V" after the Soviet-era satellite that was the first launched into space in 1957, had already received approval.

This raised concerns among Western scientists over a lack of safety data, with some warning that moving too quickly on a vaccine could be dangerous.

Russia denounced criticism as an attempt to undermine Moscow's research.

In the Lancet study, Russian researchers reported on two small trials, each involving 38 healthy adults aged between 18 and 60, who were given a two-part immunization.

Each participant was given a dose of the first part of the vaccine and then given a booster with the second part 21 days later.

They were monitored over 42 days and all developed antibodies within the first three weeks.

The report said the data showed that the vaccine was "safe, well-tolerated, and does not cause serious adverse events in healthy adult volunteers."

The trials were open label and not randomized, meaning there was no placebo and the participants knew they were receiving the vaccine and were not randomly assigned to different treatment groups.

Researchers underlined that larger and longer trials – including a placebo comparison – would be needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection.

"Showing safety will be crucial with COVID-19 vaccines, not only for vaccine acceptance but also for trust in vaccination broadly," Naor Bar-Zeev of Johns Hopkins Bloomberg School of Public Health wrote in a commentary in the Lancet.

The report said the 76 participants of these trials would be monitored up to 180 days, adding that a more rigorous phase 3 clinical trial was planned with the involvement of 40,000 volunteers "from different age and risk groups."

RECOMMENDED
Long-term use of antidepressants has been associated with an increase in heart disease. (dpa Photo)

Long-term use of antidepressants linked to increased heart disease

HEALTH
  • shortlink copied
  • Last Update: Sep 04, 2020 3:11 pm
    RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    covid-19 outbreak covid-19 vaccine russia health
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    Swedish Foreign Minister Tobias Billstrom attends a press conference after his meeting with Latvian Foreign Minister Edgars Rinkevics (not pictured) in Riga, Latvia, Jan. 27, 2023. (EPA Photo)

    Türkiye-Sweden talks on NATO bid suspended: FM Billstrom

    TÜRKIYE-SWEDEN-RELATIONS
    Italy's Prime Minister Giorgia Meloni and Libya's Tripoli-based Prime Minister Abdulhamid Dbeibah hold a joint news conference in the Libyan capital, on Jan. 28, 2023. (AFP Photo)

    Italy, Libya ink $8B gas deal during PM Meloni's visit

    Libya

    Erdoğan slams foreign media for perception management pre-elections

    Recep-Tayyip-Erdoğan

    Türkiye issues travel warning for citizens visiting EU countries

    türkiye-eu-relations
    No Image
    Charcoal production in Turkey's northwestern province Edirne
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021